Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

The Modernization of Cosmetics Regulation Act of 2022 (“MoCRA”)

Jan 30, 2023

On December 29, 2022, President Joe Biden signed into law the Consolidated Appropriations Act, 2023, which includes the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). This new cosmetic legislation establishes federal standards for cosmetic business...

Maine PFAS Reporting Deadline Approaching

Dec 8, 2022

Maine enacted a law in July 2021 requiring manufacturers of products containing intentionally added Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) to report to the Maine Department of Environmental Protection by January 1, 2023. Moreover, the sale of products...

Notice to Stakeholders concerning the Cosmetic Ingredient Hotlist

Nov 21, 2022

Health Canada is considering certain substances for inclusion in future updates to the Cosmetic Ingredient Hotlist (Hotlist). The proposal includes the following: Additions to the Hotlist Changes to the conditions for existing entries on the Hotlist Changes to include...

Amendments to the NHP Regulation

Jul 19, 2022

As recently published in the Canada Gazette, Health Canada published the final amendments to the Natural Health Products and the Food and Drugs Regulations, also known as the Self-Care Framework. These amendments are part of the Forward Regulatory Plan 2022-2024 and...

California Bill AB-2787 proposes to ban microplastics in leave-on products

Jul 4, 2022

In February 2022, the Assembly Bill 2787 was introduced. This Bill will ban the sale of specific products such as cosmetics, detergents, wax, polishes, etc., in California, if they contain intentionally added microplastics. Biodegradable and water-soluble materials...

Mandatory Section 71 (S. 71) Survey due by September 14th, 2022

Jun 27, 2022

This mandatory survey applies to your company if you manufactured or imported certain substances in Canada and meet some additional criteria. Approximately 700 substances that are on the Revised In Commerce List are subject to this notice. The notice applies to any...

Final FDA Guidance for Drugs & Biologics Containing Nanomaterials

Jun 13, 2022

If your company has nanomaterials in any drug (including OTC drugs) or biologic products sold in the US, this Guidance is important to you. The US Food and Drug Administration (FDA) has recently released its final industry guidance on human drug and biological...

Health Canada To Amend Cosmetic Regulations – Enhance Regulatory Oversight

Jun 13, 2022

Health Canada has been proposing amendments to the Cosmetic Regulations to introduce requirements to disclose certain fragrance allergens on the cosmetic product labels as well as amendments to enhance regulatory oversight for cosmetics. These amendments are part of...

New French Language Requirements per Québec – Bill 96

Jun 13, 2022

On June 1, 2022, Québec’s Bill 96 became law. While most of the amendments will come into force at a later date, some significant changes came into force immediately on June 1, 2022. As a result, most businesses operating in Québec will have to adjust their practices...

Health Canada’s Pilot Project to assess the compliance of lower risk MAHs

Jun 13, 2022

Health Canada is initiating a Pilot Program to assess the compliance of sites defined as lower risk (drugs that are not likely to generate many serious adverse drug reactions) Market Authorization Holders (MAHs). The scheduling of Good Pharmacovigilance Practices...

« Older Entries

Next Entries »

“Focal Point Research has consistently and professionally looked after regulatory and quality issues of our brand for years. Through a courteous and knowledgeable team, they have managed to navigate us through an ever changing regulatory landscape while maintaining our interests, and allowed us to correctly distribute and sell within Canada.”

“I have truly enjoyed working with you over the last 8 years! You and your team have been an amazing resource for me. I have always been impressed by the knowledge and professionalism of everyone at Focal Point, which is a true testament to your leadership.”

Connect With Us

The Focal Point Research team is ready to help with all of your scientific and regulatory needs. Our team has the experience and expertise you need to see your product to market and we are eager to help you.

181 Lakeshore Road E. Mississauga, ON

1 (905) 271 2709

mail@focalpointresearch.net

Delsie Braganza

Jennifer Porter, BA Psychology, MBA – President & CEO

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Connect With Us